PAI
PRQR icon

Palo Alto Investors’s ProQR Therapeutics PRQR Stock Holding History

Palo Alto Investors’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$351K Hold
188,807
– – 0.05% 51
2026
Q1 		$306K Hold
188,807
– – 0.05% 50
2025
Q4 		$381K Hold
188,807
– – 0.05% 47
2025
Q3 		$402K Buy
+188,807
New +$413K 0.07% 42

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Palo Alto Investors's PRQR Position: Q2 2026 in Review

Palo Alto Investors held its ProQR Therapeutics (PRQR) position steady in Q2 2026 at 188,807 shares worth $351K. The position accounts for 0.05% of the portfolio, ranked #51.

Palo Alto Investors first reported a position in PRQR in Q3 2025 and has held it in 4 quarters since. The position peaked at $402K in Q3 2025. 70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

  • Palo Alto Investors held 188,807 shares of ProQR Therapeutics worth $351K as of Q2 2026.
  • Palo Alto Investors left its ProQR Therapeutics share count unchanged in Q2 2026.
  • ProQR Therapeutics made up 0.05% of Palo Alto Investors's portfolio in Q2 2026, its #51 holding.
  • Palo Alto Investors first reported a position in ProQR Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Palo Alto Investors's ProQR Therapeutics position peaked at $402K in Q3 2025.
  • 70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on Palo Alto Investors's 13F filing for Q2 2026, filed 17 Aug 2026.